Key result
Sulphinpyrazone is linked to fewer sudden deaths in MI survivors despite equal non-fatal ischemia.
Why the study?
The effect of regular sulphinpyrazone on mortality and non-fatal cardiac ischemic episodes after acute myocardial infarction was evaluated.
Does sulphinpyrazone reduce sudden death in patients surviving an acute myocardial infarct?
Does sulphinpyrazone reduce sudden death in patients surviving an acute myocardial infarct?
Sulphinpyrazone may reduce sudden death in patients surviving an acute myocardial infarction, though it did not appear to affect non-fatal ischaemic episodes.
May support sulphinpyrazone for post-MI sudden death prevention; hypothesis-generating and should not change practice without RCTs.
SummaryTwo groups of patients surviving an acute myocardial infarct were followed up for 12 months after discharge from hospital. One group received regular sulphinpyrazone (600 mg/day) and the other did not. Two sulphinpyrazone-treated subjects died suddenly compared to 6 in the control group, whereas non-fatal acute cardiac ischaemic episodes were equally frequent in the two groups.
No takes yet. Share an insight, caveat, or question.
Tulloch et al. (1981) studied this question. Sulphinpyrazone (600 mg/day) resulted in 2 sudden deaths compared to 6 in controls among myocardial infarction survivors over 12 months, with equal rates of non-fatal ischemic episodes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: